Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL01211 Phase 1 study in healthy volunteers
NCT04908462Phase 1Completed
- Sponsor
- AceLink Therapeutics
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AL01211 in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by AceLink Therapeutics. Primary endpoint: Adverse Events and Serious Adverse Events. Started Jun 2021; status: completed.
02
Drugs
AL01211
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT04908462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908462.